Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 7
Submit an article Journal homepage
479
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates

Ehab L. Atallaha Medical College of Wisconsin, Milwaukee, WI, USAView further author information
,
Islam Sadekb Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information
,
Rodrigo Maegawab Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information
,
Xiting Caob Novartis Pharmaceuticals Corporation, East Hanover, NJ, USACorrespondence[email protected]
View further author information
,
Dominick Latremouille-Viauc Analysis Group, Inc, Montreal, CanadaView further author information
,
Irina Pivnevac Analysis Group, Inc, Montreal, CanadaView further author information
,
Carmine Rossic Analysis Group, Inc, Montreal, CanadaView further author information
,
Annie Guerinc Analysis Group, Inc, Montreal, CanadaView further author information
&
Vamsi Kotad Georgia Cancer Center at Augusta University, Augusta, GA, USAView further author information
 show all
Pages 1730-1739 | Received 16 Sep 2020, Accepted 29 Jan 2021, Published online: 01 Mar 2021

References

  • Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93(3):442–459.
  • National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, Version 2.2021. August 2020. Referenced with permission from the NCCN Guidelines® for Chronic Myelogenous Leukemia V.2.2021 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed [August 31, 2020]. Available online at www.NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, Version 1.2016. September 2015. Referenced with permission from the NCCN Guidelines® for Chronic Myelogenous Leukemia V.1.2016 © National Comprehensive Cancer Network, Inc. 2015. All rights reserved. Accessed [August 31, 2020]. Available online at www.NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846–854.
  • Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298–305.
  • National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, Version 1.2017. November 2016. Referenced with permission from the NCCN Guidelines® for Chronic Myelogenous Leukemia V.1.2017 © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed [August 31, 2020]. Available online at www.NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv41–iv51.
  • Novartis Pharmaceuticals Corporation. TASIGNA® (Nilotinib) highlights of prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2019. 1–39.
  • Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984.
  • Ritchie EK, Latremouille-Viau D, Guerin A, et al. Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective. Leuk Lymphoma. 2019;60(6):1476–1484.
  • Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):e528–e535.
  • Mahon FX, Boquimpani C, Kim DW, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018;168(7):461–470.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.